Tags

Type your tag names separated by a space and hit enter

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011).
Braz J Infect Dis. 2014 Mar-Apr; 18(2):187-95.BJ

Abstract

A total of 2484 target bacterial pathogens were collected (one per patient episode) from patients in 16 Latin American medical centers located in seven nations during 2011. Isolate identity was confirmed at a coordinating laboratory and susceptibility testing was performed for ceftaroline and comparator agents according to reference broth microdilution methods. A total of 30.0% of isolates were from respiratory tract, 29.4% from skin and skin structure, 21.4% from blood stream, 7.9% from urinary tract and 11.3% from other sites. Ceftaroline was active against Staphylococcus aureus (42.8% MRSA) with 83.6% of the isolates at ≤ 1 mg/L and all isolates at ≤ 2 mg/L (MIC5090, 0.25/2mg/L). National MRSA rates ranged from a low of 28.8% in Colombia to a high of 68.1% in Chile. All Streptococcus pyogenes and Streptococcus agalactiae were susceptible to ceftaroline (MIC50/90 values were at ≤ 0.015/≤ 0.015 mg/L for both). All Streptococcus pneumoniae were susceptible to ceftaroline, linezolid, tigecycline and vancomycin. Susceptibility to ceftriaxone was at 88.4% (CLSI non-meningitis interpretive criteria) and 73.9% (CLSI meningitis interpretive criteria) for all S. pneumoniae. Ceftriaxone susceptibility was only at 33.3% (CLSI non-meningitis interpretive criteria) and 0.0% (CLSI meningitis interpretive criteria) for penicillin-intermediate (penicillin MIC, 4 mg/L) strains. All Haemophilus influenzae (29.4% β-lactamase-positive) isolates were susceptible to ceftaroline, amoxicillin-clavulanate, ceftriaxone, and levofloxacin. For the Latin American region, the ESBL-phenotype rate was 37.6% for Escherichia coli and 53.3% for Klebsiella pneumoniae. Ceftaroline was not active against ESBL-phenotype strains but was active against >90.0% of the non-ESBL-phenotype. The spectrum of activity of ceftaroline against pathogens from Latin America indicates that it merits further study for its potential use in the Latin American region.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA, USA. Electronic address: robert-flamm@jmilabs.com.JMI Laboratories, North Liberty, IA, USA.JMI Laboratories, North Liberty, IA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24513484

Citation

Flamm, Robert K., et al. "Ceftaroline Activity Tested Against Contemporary Latin American Bacterial Pathogens (2011)." The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, vol. 18, no. 2, 2014, pp. 187-95.
Flamm RK, Sader HS, Jones RN. Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). Braz J Infect Dis. 2014;18(2):187-95.
Flamm, R. K., Sader, H. S., & Jones, R. N. (2014). Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, 18(2), 187-95. https://doi.org/10.1016/j.bjid.2013.11.005
Flamm RK, Sader HS, Jones RN. Ceftaroline Activity Tested Against Contemporary Latin American Bacterial Pathogens (2011). Braz J Infect Dis. 2014 Mar-Apr;18(2):187-95. PubMed PMID: 24513484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). AU - Flamm,Robert K, AU - Sader,Helio S, AU - Jones,Ronald N, Y1 - 2014/02/07/ PY - 2013/09/19/received PY - 2013/11/05/revised PY - 2013/11/10/accepted PY - 2014/2/12/entrez PY - 2014/2/12/pubmed PY - 2014/6/6/medline KW - AWARE KW - Ceftaroline KW - Latin America SP - 187 EP - 95 JF - The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases JO - Braz J Infect Dis VL - 18 IS - 2 N2 - A total of 2484 target bacterial pathogens were collected (one per patient episode) from patients in 16 Latin American medical centers located in seven nations during 2011. Isolate identity was confirmed at a coordinating laboratory and susceptibility testing was performed for ceftaroline and comparator agents according to reference broth microdilution methods. A total of 30.0% of isolates were from respiratory tract, 29.4% from skin and skin structure, 21.4% from blood stream, 7.9% from urinary tract and 11.3% from other sites. Ceftaroline was active against Staphylococcus aureus (42.8% MRSA) with 83.6% of the isolates at ≤ 1 mg/L and all isolates at ≤ 2 mg/L (MIC5090, 0.25/2mg/L). National MRSA rates ranged from a low of 28.8% in Colombia to a high of 68.1% in Chile. All Streptococcus pyogenes and Streptococcus agalactiae were susceptible to ceftaroline (MIC50/90 values were at ≤ 0.015/≤ 0.015 mg/L for both). All Streptococcus pneumoniae were susceptible to ceftaroline, linezolid, tigecycline and vancomycin. Susceptibility to ceftriaxone was at 88.4% (CLSI non-meningitis interpretive criteria) and 73.9% (CLSI meningitis interpretive criteria) for all S. pneumoniae. Ceftriaxone susceptibility was only at 33.3% (CLSI non-meningitis interpretive criteria) and 0.0% (CLSI meningitis interpretive criteria) for penicillin-intermediate (penicillin MIC, 4 mg/L) strains. All Haemophilus influenzae (29.4% β-lactamase-positive) isolates were susceptible to ceftaroline, amoxicillin-clavulanate, ceftriaxone, and levofloxacin. For the Latin American region, the ESBL-phenotype rate was 37.6% for Escherichia coli and 53.3% for Klebsiella pneumoniae. Ceftaroline was not active against ESBL-phenotype strains but was active against >90.0% of the non-ESBL-phenotype. The spectrum of activity of ceftaroline against pathogens from Latin America indicates that it merits further study for its potential use in the Latin American region. SN - 1678-4391 UR - https://www.unboundmedicine.com/medline/citation/24513484/Ceftaroline_activity_tested_against_contemporary_Latin_American_bacterial_pathogens__2011__ DB - PRIME DP - Unbound Medicine ER -